Date: 2016-04-12
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Hutchison China MediTech Limited (China)
Product: HMPL-689
Action
mechanism: phosphoinositide 3-kinase (PI3K) inhibitor. HMPL-689 is a novel, highly selective and potent small molecule inhibitor targeting the delta isoform of the phosphatidylinositol-3-kinase, also known as PI3Kdelta, a key component in the B-cell receptor signaling pathway.
Disease:
Therapeutic area: Cancer - Oncology
Country: Australia
Trial
details: The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers. (NCT02631642)
Latest
news: * On April 12, 2016, Hutchison China MediTech Limited announced that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated the first-in-human Phase I clinical trial of HMPL-689 in Australia. The first drug dose was administered on April 7, 2016. The FIH trial aims to evaluate the safety, tolerability, and pharmacokinetics properties of HMPL-689. This randomized, double blind, placebo-controlled, dose-escalating Phase I study of HMPL-689 will be conducted in healthy adult volunteers. Following this FIH Phase I trial, HMP plans to investigate HMPL-689 in hematological malignancies. In pre-clinical studies, not only did HMPL-689 demonstrate a superior potency and better kinase selectivity as compared to drugs in the same class, but it also showed significant efficacy and a favorable safety profile.
